SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at an offering price of $1.51 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,464,252 shares of its common stock at a price of $1.509 per pre-funded warrant.

2024年5月24日，西雅图（环球通讯社）--透视疗法公司（Perspective Therapeutics，Inc.）（“透视疗法”或“公司”）（纽约证券交易所美国证券交易所：CATX）是一家放射性药物公司，开创了全身癌症的先进治疗应用，今天宣布以每股1.51美元的发行价格包销其普通股515880股，并向某些投资者提供了以每股1.509美元的价格购买其普通股1464252股的预付认股权证。

The aggregate gross proceeds from this offering are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant.

本次发行的总收益预计约为8000万美元，扣除承销折扣和佣金以及与本次发行相关的其他应支付的发行费用。每只预缴认股权证的每股购买价格代表普通股的每股发行价格，减去该预缴认股权证每股0.001美元的行权价格。

The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions. All of the shares of common stock and pre-funded warrants to be sold in the offering are being sold by Perspective. BofA Securities, Inc., Oppenheimer & Co. Inc. and RBC Capital Markets, LLC are acting as joint book-running managers for the offering and B.

预计本次发行将于2024年5月29日左右结束，但须符合惯例的结束条件。本次发行中出售的所有普通股和预支认股权证均按透视法出售。美国银行证券公司（BofaSecurities，Inc.）、奥本海默公司（Oppenheimer&Co.Inc.）和加拿大皇家银行资本市场有限责任公司（RBC Capital Markets，LLC）担任此次发行和B。

Riley Securities, Inc. is acting as a co-manager for the offering. Perspective intends to use the net proceeds that it will receive from the offering for: (i) the continued clinical development of VMT-α-NET, VMT-01/02 and PSV359; (ii) the continued development of PSV40X and additional preclinical product candidates as well as broader development platform; and (iii) the build out, operation and expansion of manufacturing facilities, as well as for wo.

Riley Securities，Inc.担任此次发行的联合经理。Perspective打算将其从此次发行中获得的净收益用于：（i）VMT-α-net，VMT-01/02和PSV359的持续临床开发；（ii）继续开发PSV40X和其他临床前候选产品以及更广泛的开发平台；（iii）制造设施以及wo的扩建、运营和扩建。